AFFY  Affymax Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Current Price

+0.0286 (+26.88%)

Book Price

Overvalued by 301.16%
Financial Institution

Company Metrics

  • 1.3 P/E
  • 94.98 P/S
  • 0.77 P/B
  • 0.082 EPS
  • 0 / 0% Dividend
  • 488,038.00 Avg. Vol.
  • 5.1M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Affymax Reports Second Quarter 2014 Financial Results
Wall Street Journal - Jul 31, 2014
Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014. The net income for the second quarter of 2014 was $7.2 million (or $0.19 per share) compared to net income of $15.4 million (or $0.41 per share ...
An Analysis Of Amgen
Seeking Alpha (registration) - 17 hours ago
A protein-based competitor to Epogen, Omontys, from Takeda (OTCPK:TKPYY) and Affymax (OTCQB:AFFY), came to market in 2012 and after killing a few people due to severe allergic reactions, was withdrawn last year.
Adamas Pharmaceuticals Announces Management Changes
Wall Street Journal - Aug 13, 2014
Prior to Adamas, Mr. Knapp spent seven years as the Chief Commercial Officer for Affymax where he was responsible for building its U.S.
Biotech Stock Directory Update (press release) - Aug 14, 2014
Affymax, Inc. (NasdaqGS:AFFY) is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often ...
Affymax board announces decision to dissolve the company
Reuters Key Development - Jun 24, 2014